Etodolac

Nonsteroidal Anti-inflammatory Drug (NSAID) Propionic acid derivative (acetic acid derivative)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog Oral 10-15 mg/kg Once daily (q24h) Duration: For osteoarthritis: typically 5-7 days initially, then as needed. For post-operative pain: 3-7 days.
Notes: Administer with food to reduce gastrointestinal upset. Use the lowest effective dose for the shortest duration. Do not exceed 15 mg/kg/day.
Cat Oral Not recommended Not recommended Duration: Not recommended
Notes: Cats are more sensitive to NSAID toxicity. Etodolac is not approved for cats and should be avoided. If used, extreme caution and close monitoring are required, but alternative NSAIDs are preferred.
Horse Oral Not established Not established Duration: Not established
Notes: Not approved for horses. Limited studies suggest a dose of 10-20 mg/kg orally once daily, but safety and efficacy are not well defined. Use only under veterinary supervision.

Clinical Indications & Species Uses

General Indications
  • Management of pain and inflammation in dogs, primarily for osteoarthritis.
Dog (Canine)
  • Management of pain and inflammation associated with osteoarthritis
  • Post-operative pain and inflammation (off-label in some regions)

Pharmacology & Mechanism of Action

Drug Class: Nonsteroidal Anti-inflammatory Drug (NSAID) | Pharmacological Group: Propionic acid derivative (acetic acid derivative)

Mechanism of Action: Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its therapeutic effects primarily through reversible inhibition of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. It is considered a preferential COX-2 inhibitor, meaning it has greater selectivity for COX-2 than COX-1 at therapeutic doses. This selectivity reduces the synthesis of pro-inflammatory prostaglandins (e.g., PGE2) while potentially sparing gastrointestinal protective prostaglandins. The anti-inflammatory, analgesic, and antipyretic effects result from decreased prostaglandin production at sites of inflammation. Additionally, etodolac may have some inhibitory effect on neutrophil function and other inflammatory mediators.

Pharmacodynamics: Etodolac produces dose-dependent anti-inflammatory, analgesic, and antipyretic effects. In dogs, it has been shown to reduce inflammation and pain associated with osteoarthritis. Its preferential COX-2 selectivity is thought to provide a better gastrointestinal safety profile compared to non-selective NSAIDs, although gastrointestinal adverse effects can still occur. The onset of analgesia is typically within a few hours, with peak effects observed after several days of continuous therapy. Etodolac also has a relatively long duration of action in dogs, allowing for once-daily dosing.

⚡ Pharmacokinetics Summary

Absorption: Etodolac is well absorbed after oral administration in dogs and other species. In dogs, peak plasma concentrations are reached within 1-2 hours after oral dosing. Food can delay absorption but does not significantly affect overall bioavailability.
Distribution: Etodolac is highly protein-bound (>99%) in plasma. It distributes widely into tissues, including synovial fluid, where concentrations may be lower than plasma but still therapeutic. The volume of distribution is relatively small, consistent with its high protein binding.
Metabolism: Etodolac undergoes extensive hepatic metabolism. In dogs, the primary metabolic pathways include hydroxylation and conjugation (glucuronidation). Several metabolites are formed, some of which may have pharmacological activity. The metabolism is species-dependent, with differences in the rate and extent of metabolism among dogs, cats, and other animals.
Excretion: Etodolac and its metabolites are excreted primarily in the urine, with a smaller portion eliminated in feces. In dogs, approximately 70% of the dose is excreted in urine, and about 20% in feces. Biliary excretion and enterohepatic recirculation may occur.
Half-Life: Dog: approximately 7-8 hours (range 5-10 hours). Horse: approximately 1-2 hours. Other species: variable; in cats, half-life is prolonged (approximately 10-12 hours) due to slower metabolism.
Bioavailability: Oral bioavailability is approximately 80-100% in dogs. In horses, oral bioavailability is lower (around 60-70%).
Protein Binding: >99% in dogs and other species.

Available Formulations & Strengths

Oral Tablet 100 mg, 200 mg, 300 mg, 400 mg, 500 mg (Oral)
Oral Capsule 200 mg, 300 mg (Oral)
Injectable Solution (not commonly used in veterinary medicine) Not available in veterinary formulations (IV/IM (human formulation))

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to etodolac or other NSAIDs
  • Active gastrointestinal ulceration or bleeding
  • Renal insufficiency or renal disease
  • Hepatic insufficiency or hepatic disease
  • Coagulation disorders (e.g., bleeding disorders)
  • Concurrent use of other NSAIDs or corticosteroids
  • Pregnancy or lactation (unless specifically indicated and under veterinary supervision)
  • Dehydration or hypovolemia
Warnings & Clinical Precautions:
  • Use with caution in dogs with pre-existing renal, hepatic, or cardiac disease.
  • Monitor for signs of gastrointestinal toxicity (vomiting, diarrhea, melena, anorexia) during therapy.
  • Use the lowest effective dose for the shortest duration.
  • Avoid use in animals that are dehydrated, hypotensive, or have reduced blood flow to the kidneys.
  • Do not use in cats due to increased risk of toxicity.
  • Not approved for use in food-producing animals; withdrawal times are not established.
  • Administer with food to reduce gastrointestinal irritation.
  • Monitor renal function and blood counts during prolonged therapy.
  • Use with caution in young or geriatric animals.
  • Do not combine with other NSAIDs or corticosteroids due to increased risk of adverse effects.

Adverse Effects & Reactions

Common:

  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Lethargy
  • Increased thirst

Serious / Severe:

  • Gastrointestinal ulceration or perforation
  • Renal failure
  • Hepatic toxicity
  • Blood dyscrasias (e.g., aplastic anemia)
  • Neurological signs (seizures, ataxia)

Rare:

  • Allergic reactions (skin rash, anaphylaxis)
  • Coagulopathies
  • Protein-losing nephropathy

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other NSAIDs (e.g., carprofen, meloxicam) Additive risk of gastrointestinal ulceration and renal toxicity. High
Corticosteroids (e.g., prednisone) Increased risk of gastrointestinal ulceration and perforation. High
Anticoagulants (e.g., warfarin, heparin) Increased risk of bleeding due to platelet inhibition. High
Diuretics (e.g., furosemide) Reduced diuretic efficacy and increased risk of renal toxicity. Moderate
ACE inhibitors (e.g., enalapril) Reduced antihypertensive effect and increased risk of renal impairment. Moderate
Aminoglycoside antibiotics Increased risk of nephrotoxicity. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Vomiting
  • Diarrhea (possibly bloody)
  • Lethargy
  • Loss of appetite
  • Abdominal pain
  • Increased thirst and urination
  • In severe cases: seizures, coma, renal failure, gastrointestinal perforation

Emergency Treatment Protocol: Treatment is primarily supportive and symptomatic. Induce emesis if ingestion was recent (within 2 hours) and the animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids to maintain hydration and renal perfusion. Monitor renal function, liver enzymes, and blood counts. Use gastroprotective agents (e.g., misoprostol, omeprazole) to prevent or treat gastrointestinal ulceration. In severe cases, consider hemodialysis or peritoneal dialysis. There is no specific antidote for etodolac overdose.

Food Animal Withdrawal Times

Etodolac is not approved for use in food-producing animals. No withdrawal times have been established. Use in food animals is prohibited or requires a very long withdrawal period based on veterinary discretion and regulatory guidelines.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved by the FDA for use in dogs (e.g., Etogesic®). Not approved for other species.

Extra-Label (Off-Label) Use: In the United States, etodolac is approved for use in dogs only. Extra-label use in other species is permitted under the Animal Medicinal Drug Use Clarification Act (AMDUCA) only with a valid veterinarian-client-patient relationship and appropriate withdrawal times, but no withdrawal times are established for food animals. Use in cats is considered extra-label and is not recommended due to safety concerns.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Etodolac is a preferential COX-2 inhibitor NSAID used primarily for the management of pain and inflammation associated with osteoarthritis in dogs. It is administered orally once daily, with a dose of 10-15 mg/kg. Clinical response is typically seen within a few days, and therapy should be continued for at least 5-7 days to assess efficacy. It is important to use the lowest effective dose for the shortest duration to minimize adverse effects. Gastrointestinal and renal adverse effects are the most concerning, especially in animals with pre-existing conditions. Baseline blood work (CBC, biochemistry profile, urinalysis) is recommended before starting therapy, and periodic monitoring is advised during long-term use. Etodolac should not be used in cats due to a narrow margin of safety. In horses, its use is not well studied, and alternative NSAIDs are preferred. For food animals, etodolac is not approved, and no withdrawal times are available, so its use is contraindicated. Always consider the animal's hydration status and renal function before administration. If signs of toxicity occur, discontinue the drug and provide supportive care.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)